cookies-img
We use third-party cookies to provide support. By continuing to browse this website, you accept our privacy policy.
close-icon
Gilead Sciences Inc
173 own
159 watching
Current Price
$77.01
$0.5
(0.65%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Market Capitalization
Market Capitalization
85,594.08M
52-Week High
52-Week High
87.87000
52-Week Low
52-Week Low
62.07000
Average Volume
Average Volume
7.45M
Dividend Yield
Dividend Yield
0.04237
P/E Ratio
P/E Ratio
11.3194
iconMarket Capitalization85,594.08M
icon52-Week High87.87000
icon52-Week Low62.07000
iconAverage Volume7.45M
iconDividend Yield0.04237
iconP/E Ratio11.3194
What does the Gilead Sciences Inc do?
Gilead Sciences, Inc., a research-based biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical needs in Europe, North America, Asia, South America, Africa, Australia, India, and the Middle East. The company's products include Descovy, Odefsey, Genvoya, Stribild, Complera/Eviplera, Atripla, Truvada, Viread, Emtriva, Tybost, and Vitekta for the treatment of human immunodeficiency virus (HIV) infection in adults; and Vemlidy, Epclusa, Harvoni, Sovaldi, Viread, and Hepsera products for treating liver diseases. It also offers Zydelig, a PI3K delta inhibitor, in combination with rituximab, for the treatment of certain blood cancers; Letairis, an endothelin receptor antagonist for the treatment of pulmonary arterial hypertension; Ranexa, a tablet used for the treatment of chronic angina; Lexiscan/Rapiscan injection for use as a pharmacologic stress agent in radionuclide myocardial perfusion imaging; Cayston, an inhaled antibiotic for the treatment of respiratory systems in cystic fibrosis patients; and Tamiflu, an oral antiviral capsule for the treatment and prevention of influenza A and B. In addition, the company provides other products, such as AmBisome, an antifungal agent to treat serious invasive fungal infections; and Macugen, an anti-angiogenic oligonucleotide to treat neovascular age-related macular degeneration. Further, it has product candidates in various stages of development for the treatment of HIV/AIDS and liver diseases, such as hepatitis C virus and hepatitis B virus; hematology/oncology; cardiovascular; and inflammation/respiratory diseases. The company markets its products through its commercial teams and/or in conjunction with third-party distributors and corporate partners. Gilead Sciences, Inc. has collaboration agreements with Bristol-Myers Squibb Company, Janssen R&D Ireland, Japan Tobacco Inc., and Galapagos NV. The company was founded in 1987 and is headquartered in Foster City, California.
Read More
How much money does Gilead Sciences Inc make?
News & Events about Gilead Sciences Inc.
TipRanks Financial Blog
1 year ago
Analysts have been eager to weigh in on the Healthcare sector with new ratings on Amneal Pharmaceuticals (AMRX Research Report), Replimune Group ... Analysts have been eager to weigh in on the Healthcare sector with new ratings on Amneal Pharmaceuticals (AMRX Research Report), Replimune Group...
Zolmax
1 year ago
Hennion & Walsh Asset Management Inc. lifted its position in Gilead Sciences, Inc. (NASDAQ:GILD Free Report) by 7.9% in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 36,569 shares of the biopharmaceutical ...
Ticker Report
1 year ago
Altfest L J Co. Inc. trimmed its position in shares of Gilead Sciences, Inc. (NASDAQ:GILD Free Report) by 7.4% during the first quarter, according to the company in its most recent Form 13F filing with the Securities Exchange Commission. The institutional investor owned 3,747 ...
Business Wire
1 year ago
Gilead Sciences, Inc. (Nasdaq: GILD) today announced Week 96 results from the pivotal MYR301 Phase 3 clinical trial evaluating the first-in-class entry inhibitor Hepcludex (bulevirtide) for the treatment of adults with chronic hepatitis delta (HDV) infection. These new data presented at the...
Business Wire
1 year ago
Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion for Trodelvy (sacituzumab govitecan) as monotherapy for the treatment of adult patients with unresectable or...
Frequently Asked Questions
Frequently Asked Questions
What is Gilead Sciences Inc share price today?
plus_minus_icon
Can Indians buy Gilead Sciences Inc shares?
plus_minus_icon
How can I buy Gilead Sciences Inc shares from India?
plus_minus_icon
Can Fractional shares of Gilead Sciences Inc be purchased?
plus_minus_icon
What are the documents required to start investing in Gilead Sciences Inc stocks?
plus_minus_icon
What is today’s traded volume of Gilead Sciences Inc?
plus_minus_icon
What is today’s market capitalisation of Gilead Sciences Inc?
plus_minus_icon
What is the 52-Week High and Low Range of Gilead Sciences Inc?
plus_minus_icon
What percentage is Gilead Sciences Inc down from its 52-Week High?
plus_minus_icon
What percentage is Gilead Sciences Inc up from its 52-Week Low?
plus_minus_icon
Current Price
$77.01
$0.5
(0.65%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Related Stocks
GSK PLC-SPON ADR.
GSK PLC-SPON ADR.
$39.86
$0.79 (2.02 %)
Bristol-Myers Squibb Co.
Bristol-Myers Squibb Co.
$50.40
$5.13 (11.33 %)
AstraZeneca PLC
AstraZeneca PLC
$78.15
$-0.37 (-0.47 %)
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
$495.26
$3.00 (0.61 %)
Sign up and dive into a whole new world of investing.
Join over 370,000 who have signed up and are using Stockal successfully already.
Related Stocks
GSK PLC-SPON ADR.
GSK PLC-SPON ADR.
$39.86
$0.79 (2.02 %)
Bristol-Myers Squibb Co.
Bristol-Myers Squibb Co.
$50.40
$5.13 (11.33 %)
AstraZeneca PLC
AstraZeneca PLC
$78.15
$-0.37 (-0.47 %)
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
$495.26
$3.00 (0.61 %)
Sign up and dive into a whole new world of investing.
Join over 370,000 who have signed up and are using Stockal successfully already.

              Borderless Softtech Pvt Ltd ("BSPL") licenses and offers the Stockal Platform to subscribers and users who are based in India and wish to make global transactions. Such subscribers and users may be offered annual or monthly subscription plans by BSPL and in such cases, BSPL acts as their service provider.

              Borderless Investing Inc., (“Borderless Investing”), the owner of the Stockal Platform, is not a broker-dealer nor an investment advisor and through its affiliate stockbroker Stockal Securities Pvt. Ltd., (SEBI INZ000301236), acting as the introducing entity has entered into a clearing agreement with DriveWealth LLC., to offer U.S. equities on the Stockal Platform. The Stockal Platform enables investments in a diverse set of global assets from a single account from anywhere in the world. As such, Borderless Investing makes no warranties or representations, express or implied, on products and services offered through its website/platform. It accepts no liability for any damages or losses, however, caused in connection with the use of related services.

              All investments involve risk and returns will fluctuate, are subject to market volatility and may cause losses. The material on this website/platform is provided solely for informational and educational purposes and shall not in any manner be considered a recommendation or endorsement of any strategy or investment, nor an offer to sell or a solicitation of an offer to buy securities, products or services nor advice. Borderless Investing makes no guarantee as to the currency, accuracy, or quality of information published and/or archived on this website/platform, nor will Borderless Investing accept any responsibility for other organizations, businesses, and private persons that provide information on this website/platform. All information on this website/platform regarding products and services provided by Borderless Investing is subject to change without notice. Reasonable efforts are taken to ensure the accuracy and integrity of all information provided here, but Borderless Investing is not responsible for misprints, out of date information, or errors. Any investment decision and/or strategy that investors make or employ, whether or not such decision or strategy derives from or relies upon material accessed or provided through this website/platform, is undertaken at the investor’s sole discretion and risk. Before making any investment decisions, investors should consult additional sources of information and/or their legal or tax advisor. PLEASE READ THIS FULL DISCLOSURE CAREFULLY BEFORE USING THIS SERVICE. BY USING THE SERVICE OR CLICKING AGREE YOU ARE AGREEING TO BE BOUND BY THESE DISCLOSURES AND ALL TERMS AND CONDITIONS ON THIS WEBSITE/PLATFORM.

              *DriveWealth LLC., a member of the Securities Investor Protection Corporation (SIPC), will serve as the custodian for your securities account. In the event that DriveWealth LLC., fails and is placed in liquidation under the Securities Investor Protection Act, securities in your brokerage account may be protected up to $500,000. For details, please see www.sipc.org.

              All brands and logos used on this website are the property of their respective owners.

              Get Started with as little as $1.00